GSK (GSK.US) "Mubilizumab" has been approved for a new indication in China.

Chronic sinusitis accompanied by nasal polyps is a chronic inflammatory disease of the nasal cavity or sinuses, which can lead to the growth of soft tissues known as nasal polyps, usually characterized by an increase in eosinophil levels.

Zhitong FinanceJan 2 21:22

GlaxoSmithKline (GSK.US) has submitted for the market approval of its ultra-long-acting IL-5 monoclonal antibody in China.

The CDE website shows that GlaxoSmithKline (GSK.US) has applied for the market launch of depemokimab in the country.

Zhitong FinanceJan 1 18:50

Express News | STIFEL has raised the Target Price for GlaxoSmithKline from $153 to $175.

BreakingsDec 31, 2024 19:57

Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

GlobeNewswireDec 26, 2024 22:00

The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.

On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.

Gelonghui FinanceDec 24, 2024 14:58

Pfizer's Progress on C. Diff Vaccine and Pneumococcal Shot Wins Analyst Conviction

Analyst UpgradesDec 24, 2024 02:20